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Abstract: Ten physically active subjects underwent two cycling exercise trials. In the first, aerobic
capacity (VO2max) was determined and the second was a 45 min submaximal exercise test. Urine
samples were collected separately the day before (day 1) , the day of (day 2), and the day after
(day 3) the submaximal exercise test (12 samples per subject). Metabolomic profiling of the samples
was carried out using hydrophilic interaction chromatography (HILIC) coupled to an Orbitrap
Exactive mass spectrometer. Data were extracted, database searched and then subjected to principle
components (PCA) and orthogonal partial least squares (OPLSDA) modelling. The best results were
obtained from pre-treating the data by normalising the metabolites to their mean output on days 1
and 2 of the trial. This allowed PCA to separate the day 2 first void samples (D2S1) from the day 2
post-exercise samples (D2S3) PCA also separated the equivalent samples obtained on day 1 (D1S1
and D1S3). OPLSDA modelling separated both the D2S1 and D2S3 samples and D1S1 and D1S3
samples. The metabolites affected by the exercise samples included a range of purine metabolites
and several acyl carnitines. Some metabolites were subject to diurnal variation these included bile
acids and several amino acids, the variation of these metabolites was similar on day 1 and day 2
despite the exercise intervention on day 2. Using OPLS modelling it proved possible to identify a
single abundant urinary metabolite provisionally identified as oxo-aminohexanoic acid (OHA) as
being strongly correlated with VO2max when the levels in the D2S3 samples were considered.
Keywords: exercise metabolomics; high resolution mass spectrometry; purines; acylcarnitines;
VO2max
1. Introduction
Physical activity and exercise have a major impact on health [1] and can reduce the incidence
of several diseases including cardiovascular disease (CVD) [2], diabetes [2], and mild-to-moderate
depression [1]. The World Health Organisation has reported that CVDs are the leading cause of
mortality (17.5 million deaths) followed by diabetes (1.5 million deaths) [3]. In the UK this is equates
to more than 200,000 (37% of total) deaths due to CVD per annum [4]. The five leading global risk
factors for death from CVD are: high blood pressure (13%), tobacco use (9%), high blood glucose (6%),
physical inactivity (6%), and overweight/obesity (5%) [5]. These risks can be modified by choice of
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diet, moderation of alcohol use, and regular physical activity. It has been estimated that the indirect
cost of physical inactivity in England is £8.2 billion per annum [6], in developed countries this is
1.5%–3% of total direct healthcare costs [7]; Scotland is one of the least physically active countries in
Europe [8].
The type of exercise which is optimal for individuals of different cohorts (e.g., sedentary vs.
already active) largely remains to be explored as do the molecular mechanisms underlying health
improvement through exercise. Exercise optimisation may depend on various factors including
gender, age, life-style, and body mass index (BMI). Directly investigating the effect of exercise on
the human metabolome by using metabolomics could provide an insight into phenotypic responses
and might allow personalised training regimes that are reflective of the initial metabolic status of
each individual. [9]. Given that cardiorespiratory fitness is strongly associated with morbidity and
mortality outcomes [10], assessing the effects of exercise on the human metabolome may also yield
vital diagnostic and prognostic indicators for clinicians. Cardiorespiratory fitness is most commonly
expressed as the maximal rate of oxygen consumption (VO2max) which can be determined during by
measuring respiratory variables during an incremental exercise test to exhaustion. Of further interest
is that VO2max is also a primary determinant of endurance exercise performance [11].
Following on from our pilot study on the acute impact of exercise on individuals [12] we conducted
a carefully controlled follow up study with 10 participants with a slightly modified exercise protocol.
We utilised our well established hydrophilic interaction chromatography-mass spectrometry method
to carry out the analysis [13–16]. The primary aim was to establish the effects of exercise on the human
metabolome using a bout of exercise that was standardised to a relative intensity. The secondary aim
was to explore potential predictive markers for VO2max.
2. Materials and Methods
2.1. Chemicals and Solvents
HPLC grade Acetonitrile (ACN) was purchased from Fisher Scientific (Loughborough, UK) and
HPLC grade water was produced by a Direct-Q 3 Ultrapure Water System (Millipore, Watford, UK).
AnalaR-grade formic acid (98%) was obtained from BDH-Merck (Poole, UK). Authentic stock standards
were prepared as stated previously in the literature [15] and diluted four times with ACN before
LC-MS analysis. Ammonium carbonate was purchased from Sigma-Aldrich (Poole, UK).
2.2. Subjects and Experimental Design
Ten healthy recreationally active adults, two female, eight male (mean ˘ S.D. (minimum–
maximum) age 28˘ 7 (23–48) years.; stature, 167˘ 30 (165–189) cm; body mass, 68.5˘ 14.7 (54.5–107.5)
kg; VO2max, 42.1 ˘ 5.4 (33.5–53.4)mL/kg
´1/min´1; maximal cycling work rate (WRmax) 134 ˘ 61
(155–369) W) volunteered and provided written informed consent to participate in the study, which
was approved by the ethics committee of the School of Science and Sport, University of the West of
Scotland. Participants recruited were staff and students from the University of the West of Scotland,
Hamilton Campus and all had previously taken part in several maximal exercise tests. All procedures
were conducted in accordance with the declaration of Helsinki.
Each participant visited the laboratory on two separate occasions to complete two cycling exercise
trials. Trials were separated by at least five, but no more than 10 days. The first trial was an incremental
exercise test until exhaustion in order to determine aerobic capacity (VO2max) and the second was a
45 min submaximal exercise test. Urine samples were collected the day before, the day of, and the day
after the submaximal exercise test (Figure 1). Participants were asked not to exercise 24 h prior to the
maximal test and for the duration of the urine collection period other than the submaximal trial. They
were also asked to refrain from the consumption of alcohol 24 h before each test, caffeine for 6 h before
testing, or consume anything other than water for 3 h before testing.
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Figure 1. Indicative representation of urine collection schematic. The first urine sample on each day
was the first pass after waking (typically 6 am–8 am).
2.3. VO2max Test
On their first visit after standard anthropological measurements, VO2max and WRMax were
measured using a continuous graded exercise test on an electronically braked cycle ergometer (Lode
Excalibur, Groningen, The Netherlands) maintaining an initial workload of 50 W. Work rate was
increased in a ramp protocol at a rate of 15 W/min until the participant could no longer maintain a
cadence of 50 revolutions per minute at which point the test was stopped. Throughout the test, heart
rate was measured by telemetry (Polar Electro Oy, Kempele, Finland) and expired gas was measured
breath by breath via indirect calorimetry (Medgraphics, Milan, Italy) and analysed for respiratory
variables. The indirect calorimeter was calibrated immediately prior to each test using calibration
and reference gases (calibration gas: 12% O2, 5% CO2; reference Gas: 21% O2, 0% CO2). Volume
was calibrated using a 3 L syringe. Following data collection, VO2 data was filtered to delete values
that were less than or greater than the rolling seven breath mean ˘ two standard deviations. All 10
participants obtained a plateau in VO2 (as determined by a rise in VO2 of <50% of the expected increase
for the given WR) fulfilling the criteria for VO2max [16]. Seven of the 10 participants achieved a true
plateau in VO2 (defined as no increase or a reduction in VO2 despite increased WR). Although rating
of perceived exertion was not recorded in the present study, all 10 particpants also achieved two of
the three secondary criteria for the determination of VO2max. Specifically, the respiratory exchange
ratio (ratio between carbon dioxide production and VO2) exceeded 1.10 and heart rate at the end of the
maximal exercise test was within 10 beats/min of the theoretical maximum (determined by 220 ´ age).
Smoothed data was subsequently averaged over a rolling seven breath mean and the largest value
obtained was determined as the participant’s VO2max.
2.4. Submaximal Test
Participants cycled on an electronically braked cycle ergometer at light and moderate intensities
for a total duration of 45 min. The exercise protocol comprised of a 5 min warm up at 50 W, 15 min at
40% of WRMax (established from the initial VO2max test), 15 min at 50% WRMax, and 10 min at 60%
WRMax. Heart rate and expired gas were continuously monitored throughout as previously described.
2.5. Sample Collection and Preparation
Coded pre-labelled sterilised urine containers, Eppendorf tubes, disposable pipettes, and ziplock
bags were distributed to the subjects. Subjects collected their first urine pass after waking (sample
1) on the day before, the day of, and the day after the submaximal exercise session. Typically the
first sample was collected between 6 am and 8 am The time of the remaining urine collections was
standardized as illustrated in Figure 1. Subjects were not restricted from urinating at any other time
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outside the sample windows for ethical reasons. Urine samples collected between 11 am and 17 pm
were transferred to Eppendorf tubes within 5 min and deposited in a laboratory freezer at ´80 ˝C
until analysis. First pass samples and 21 pm samples were collected at home. The Eppendorf tubes
were deposited inside sealed ziplock bags in the subject’s home freezer (~´20 ˝C) within 5 min of
collection. Following completion of the study, the samples were transferred to a polystyrene freezer box
surrounded by ice and ice blocks and transported to the laboratory freezer where they remained until
analysis. Samples were thawed at room temperature and prepared for LC-MS analysis. Urine (200 µL)
was thoroughly mixed with 800 µL of ACN, followed by centrifugation at 7840 relative centrifugal
force for 5 min; 800 µL of supernatant was then transferred to a LC auto-sampler vial (Thermo Fisher,
Loughborough, UK). The instrumental variation was also minimised by running the 12 samples for
each subject in blocks. Since the final normalisation is subject specific, rather than being based on the
full cohort this reduces the impact of technical variations in a long run. Samples are designated as
follows D = day, S = sample number within a day e.g., D1S1 = day 1 sample 1. Pooled samples were
interspersed throughout the run to check for technical variation. Within the blocks of 12, the samples
were randomised. Four standard mixtures containing 252 standards were run also after the samples.
2.6. LC-MS Method
LC-MS data were acquired on an Dionex 3000 HPLC (Thermo Fisher Scientific, Hemel Hempstead,
UK) coupled to an Exactive Orbitrap (Thermo Fisher Scientific) in both positive and negative mode set
at 50,000 resolution (controlled by Xcalibur version 2.1.0; Thermo Fisher Scientific, Hemel Hempstead,
UK). The mass scanning range was m/z 75–1200, the capillary temperature was 320 ˝C and the sheath
and auxiliary gas flow rates were 50 and 17 arbitrary units, respectively. The separation was performed
on a ZIC-pHILIC column (150 mm ˆ 4.6 mm, 5 µm from HiChrom, Reading, UK) in binary gradient
mode. The mobile phase used was 20 mM ammonium carbonate buffer (pH 9.2) and pure ACN; the
flow rate was 300 µL¨min´1. The gradient was programed as follows: 0 min 20% A 80% B to time
30 min 80% A 20% B. The injection volume was 10 µL and the sample tray temperature was controlled
at 12 ˝C during the measurement. Samples were run in a stratified method with between subject
samples placed in randomised order. MS2 spectra were obtained at 35 V by using an LTQ-Orbitrap
under the same conditions described for the Exactive Orbitrap.
2.7. LC-MS Data Processing and Statistical Analysis
Raw LC-MS files were processed by using m/z Mine 2.14 [17] and the accurate masses were
searched against an in house metabolite database prepared by including data from the Human
Metabolome database, Lipid Maps and the Metlin database. Graphical representations, tabular
features and statistical analysis (p-value generation) were performed in Excel (Microsoft Office 2013).
The mean of the peak areas for each metabolite across the samples within each day was calculated
and then the area for each metabolite was divided by the mean. This provided a subject-specific
normalisation within the non-exercise and exercise days. All subsequent metabolite responses, paired
t-test and fold changes (ratio) were conducted on the new data set. The raw data files can be accessed
on the Metabolights website [18] with the identifier number MTBLS306.
2.8. Multivariate Analysis
SIMCA-P version 14.0 (Umetrics, Sweden) was used for multivariate analysis which included
PCA, OPLS-DA and Orthogonal Partial Least Squares (OPLS). The data were centred, and Pareto scaled
for PCA and OPLS-DA and OPLS in order to generate S-plots for visualisation of the components with
significant influence in the dataset.
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3. Results
3.1. Physiological Responses to Submaximal Exercise
The mean VO2 at 40%, 50%, and 60% of WRmax was 21.2 ˘ 2.5 mL/kg
´1/min´1,
25.8 ˘ 2.5 mL/kg´1/min´1, and 30.8 ˘ 4.1 mL/kg´1/min´1, respectively. The mean HR during
the submaximal exercise test was 115 ˘ 12.8 bpm, 156 ˘ 14 bpm, and 169 ˘ 13.6 bpm and 40%, 50%,
and 60% or WRmax, respectively.
3.2. Metabolite Profiling
Longitudinal sampling of urine provides a non-invasive method of sample collection that provides
rich data sets and produces samples with greater volume than plasma, as well as containing higher
concentrations of particular metabolite over the period between samplings. In contrast, even if plasma
is taken frequently it will always represent an open system where taking a sample at a slightly different
time might give a different answer. In this study we used a 37 h protocol (Figure 1) in order to generate
an understanding of the acute effects of exercise and the duration of that response in the metabolite
profiles. In addition, sampling on the pre-exercise day allowed observation of metabolite variations
occurring as a diurnal rhythm. The samples were run in blocks of 12 samples for each individual with
the samples randomised within each block. This method of running minimises instrumental drift since
the instrument only has to remain stable over each block of 12 samples since the normalisation process
for the individual within removes instrumental effects in relation to earlier or later blocks.
The output from data extraction followed by searching against the data base yielded metabolites
which were identified to MSI levels 1 or 2 [19] according to either exact mass (with <3 ppm deviation)
or exact mass plus retention time matching to a standard.There was no classification of the samples
by PCA when the raw data was used as the basis of the model and it was also not possible to fit an
OPLSDA model to the raw data was used. This was in line with our experience in our pilot study [12]
where the was no separation in the PCA model when the raw data was used. In addition, in the
previous study normalisation against creatinine did not make any difference to the fit of the model
and it was concluded as has been observed by others that creatinine normalisation is not always
effective [20].
Thus, in order to compare metabolites on the same axis, the areas for each metabolite across all
the time-points for day 1 and day 2 were averaged for each individual and then each metabolite area
at each time-point was divided by the average to give the proportion contributed to the total output
during the day. This approach was similar to that used in our previous study and was discussed at
some length in that paper [12]. Figure 2 shows the PCA separation of 19 out 20 samples in the study for
the D2S1 and D2S3 following normalisation to individual metabolic output over the five urine samples
collected during day 2. One sample was excluded because there were problems with the analytical run.
It is clear that there is a marked difference in metabolite profile between the two groups. The same
comparison on day 1 between the first (D1S1) and third (D1S3) samples of the day, where there was no
exercise intervention, gave a clear separation if one individual’s samples (GS) were excluded from
the model (Figure 3). Table S1 summarises univariate comparisons for all the metabolites that are
significantly changed between D2S3 in comparison with the rest of the day 2 samples and D1S3 and
the rest of the day1 samples. There are a large number of changes and in order to get a clearer picture
of the differences between the first and third samples on day 2 and day OPLSDA models of the data
were made. Such models emphasise the importance of key variables as variables of importance (VIPs).
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Figure 2. Separation of D2S3 (green) from the post exercise D2S1 samples (blue) by using PCA
(R2X (cum) 0.548 Q2 (cum) 0.295, three components) following normalisation to individual metabolic
output on day 2.
 
Figure 3. Separation of day 1 first void (D1S1 blue) and third samples (D1S3 green) by using PCA
(R2X(cum) 0.536, Q2 (cum) 0.263, three components).
There was a very clear separation of D2S1 and D2S3 (Figure 4) obtained by using OPLSDA for
classifying D2S1/D2S3 samples. The cross validation plot indicated a strong model as can be seen
in Figure S1 where all the points for the blue squares are below the blue square on the right and the
plot intersects the y-axis below 0, and the CV ANOVA score for the model was 0.0029. However, a
clear separation was also found between the D1S1 and D1S3 samples and the cross validation model
for this was also good (Figure 5 and Figure S2), and the CV ANOVA for this model was 0.00097.
Thus the composition of the metabolites in urine varies markedly throughout the day whether exercise
is used as an intervention or not. Figure S3 shows an S-plot highlighting the features with the most
impact (largest VIPs) on the OPLSDA model for the D2S3 and D2S1 samples and table S2 lists the
highlighted metabolites. In many cases, exact identity of these features is poorly defined. However,
some of the metabolites match the retention times of analytical standards or are well known urinary
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metabolites. Table 1 shows the metabolites which are important in the OPLSDA model shown in
Figure 4 and can be identified with some confidence, the majority have p-values < 0.05. Application
of the Benjimini-Hochberg FDR statistical test [21,22] with Q = 0.1 and including 1000 metabolites
indicated that all metabolites with a p-value < 0.05 can be regarded as being significantly changed
following exercise. Figure S4 shows an S-plot highlighting the features with the most impact on
the OPLSDA model for the D1S1 and D1S3 samples and table S3 lists the metabolites with VIP
values > 1.5. Some of the important changes in metabolites between the equivalent time points on day
1 and day 2 are similar.
 
Figure 4. Separation of D2S1 (blue) and D2S3 (green) samples by using OPLSDA. R2X (cum) 0.35,
R2Y (cum) 0.99, Q2 (cum) 0.77), three components). Based on 3078 features.
 
Figure 5. Separation of D1S1 (blue) and D1S3 (green) by OPLSDA (R2X (cum) 0.56, R2Y (cum) 0.997,
Q2 (cum) 0.847, four components). Based on 3540 features.
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Table 1. Metabolites differing between D2S1 and D2S3 in comparison with D1S1 and D1S3.
Polarity m/z Rt Metabolite
p-Value***
D2S1D2S3
Ratio
D2S3D2S1
p-Value***
D1S1D1S3
Ratio
D1S3D1S1
Purine Metabolism
+ 137.046 10.8 * Hypoxanthine <0.001 3.75 0.516 0.832
+ 152.057 13.1 * Guanine 0.02 2.56 na na
´ 167.021 13.5 * Urate 0.015 0.748 <0.001 0.534
´ 181.037 10.8 1-Methyluric acid 0.01 0.59 0.012 0.561
+ 253.093 9.2 Deoxyinosine 0.01 4.97 na na
+ 269.088 11.5 * Inosine 0.02 16.27 0.947 0.967
+ 285.083 13.1 * Xanthosine 0.01 2.33 0.012 0.506
+ 282.12 13.9 Methyladenosine 0.24 0.856 <0.01 0.516
+ 296.136 17.8 Dimethyladenosine 0.20 2.390 <0.01 0.491
+ 312.13 9.2 Dimethylguanosine 0.90 0.983 <0.003 0.562
Neurotransmitter Metabolism
´ 101.024 12.7 Oxobutanoate 0.030 1.212 0.690 0.953
+ 104.071 14.9 * 4-Aminobutanoate < 0.001 0.737 0.003 0.801
´ 182.997 17.0 Hydroxybutyric acid sulfate <0.001 2.172 0.519 1.133
+ 198.113 16.8 * Metanephrine 0.082 3.000 0.074 0.762
´ 246.992 12.8
Dihydroxy phenyl acetic acid
sulfate or isomer
0.020 1.442 0.513 1.212
´ 261.007 10.5 Homovanillicacid sulfate 0.142 1.397 0.857 0.932
´ 263.023 8.5
Methoxyhydroxy
phenylethyleneglycol sulfate
0.071 1.385 0.405 0.833
Collagen Metabolism
+ 173.092 13.3 Glycylproline <0.001 0.54 0.820 1.064
+ 189.123 13.6 Glycylleucine <0.001 0.72 0.001 0.370
Sugar Metabolism
´ 87.0092 8.6 * Pyruvate 0.256 1.179 0.017 0.565
´ 89.0242 10.2 * Lactate 0.02 2.19 0.867 1.04
´ 151.061 13.6 * Xylitol or isomer 0.016 0.734 0.036 0.617
´ 163.061 9.9 * Rhamnose or isomer 0.025 0.667 <0.01 0.629
165.04 8.9 Arabinonate 0.023 0.648 <0.01 0.520
´ 181.072 14.7 * Sorbitol or isomer 0.05 0.70 0.126 0.653
´ 193.036 15.2 * Glucuronate or isomer 0.018 0.628 0.024 0.641
Fatty Acid Conjugates
´ 202.109 5.8 ‡Hydroxyhepatonyl glycine <0.01 1.76 0.238 1.276
+ 218.139 6.0 Propanoylcarnitine 0.03 0.360 0.363 1.124
+ 288.217 6.4 Octanoylcarnitine 0.5397 1.115 0.002 0.540
+ 300.218 6.0 Nonanoyl carnitine 0.015 1.63 0.499 0.850
+ 314.234 5.6 Decanoyl carnitine 0.01 1.56 0.391 0.825
+ 330.227 6.6 Keto-decanoylcarnitine 0.032 1.61 0.499 0.850
Steroids
´ 367.158 3.9 Testosterone sulfate 0.04 1.57 0.319 1.23
´ 539.25 6.7
Tetrahydroaldosterone
glucuronide
<0.01 1.62 0.369 1.21
Bile Acids
´ 405.265 5.6 Dihydroxyoxocholanate <0.01 0.44 0.078 0.512
´ 407.281 6.6 Cholic acid <0.01 0.34 <0.01 0.340
´ 583.312 10.3 Cholic acid glucuronide <0.01 0.27 < 0.01 0.170
´ 583.312 11.5 Cholic acid glucuronide <0.01 0.23 <0.01 0.170
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Table 1. Cont.
Polarity m/z Rt Metabolite
p-Value***
D2S1D2S3
Ratio
D2S3D2S1
p-Value***
D1S1D1S3
Ratio
D1S3D1S1
Amino Acids and Their Metabolites
´ 118.051 12.0 * Threonine <0.01 0.64 0.685 1.06
´ 131.046 15.8 * Asparagine <0.01 0.76 0.879 1.05
+ 132.102 11.3 * Leucine 0.030 0.593 0.061 0.675
´ 148.043 14.0 * Methionine <0.01 0.58 0.061 0.675
+ 161.128 23.0 Methyllysine 0.114 1.526 0.002 2.669
´ 172.098 6.1 N-Acetylleucine <0.01 0.65 0.010 0.590
+ 175.108 9.3 ** N-Acetylornithine isomer <0.01 0.70 < 0.01 0.566
´ 187.072 11.4 * N-Acetylglutamine <0.01 0.67 < 0.01 0.628
+ 221.092 6.8
** 5-Hydroxytryptophan
isomer
0.06 2.24 0.530 0.952
´ 214.028 14.0 Chlorotyrosine 0.04 2.09 <0.01 2.91
´ 216.099 11.8 N-Acetylcitrulline <0.01 0.60 <0.01 0.570
+ 219.134 13.7 Carboxyethyllysine <0.01 0.65 <0.01 0.467
+ 247.14 15.0 Carboxyethylarginine <0.01 2.23 0.022 0.544
Vitamins and Co-Factors
+ 132.077 15.4 * Creatine 0.011 0.538 0.018 0.440
+ 220.118 9.4 * Pantothenate <0.01 1.40 <0.01 0.529
´ 375.13 8.1 * Riboflavin 0.013 0.66 0.032 0.500
Microbial Metabolites
´ 153.02 14.0 Dihydroxybenzoate 0.078 1.324 0.884 0.964
´ 192.067 6.0 Phenylacetylglycine <0.01 1.76 0.277 0.756
´ 197.046 9.8 Dihydroxyphenyllactate 0.025 1.43 0.383 0.855
* Matches retention time of standard. ** Same elemental composition as the standard but different retention
time. na = not detected in these samples. Matches retention time of standard. na = not detected in these
samples. ‡Same elemental composition as acetyl carnitine but retention time much earlier. *** Application of
the Benjamin-Hochberg false discovery rate with Q = 0.1 and including 1000 features in the test indicated that
all p-values < 0.05 are significant.
Thus, overall, the number of changes observed as a result of exercise were fewer than in our
previous smaller study but some of the changes were consistent with our previous observations
particularly with regard to the impact on several purine metabolites and effects on carnitines [12].
In the current study the level of exercise was more carefully controlled than in our previous study and
the subjects were in a narrow age range. The additional measurement which was made in the current
study was the determination of of VO2max for each of the subjects.
OPLS modelling was used to predict VO2max from the metabolic pattern in urine post-exercise.
A weakly fitted model was built by using the D2S3 and day 2 fourth samples (D2S4) samples and then
discarding variables of low importance with VIP values < 1. There seems to be no standard way to
build such models and it is easy to be misled with regard to their robustness when several variables
are used. It is quite surprising how easy it is for software to fit a model based on even a few variables
when the number of samples is low. Eventually, by reducing the number of variables, it was possible to
produce a plot of predicted against measure VO2max based on a single putatively identified as being an
oxoaminohexanoic acid (OHA) (Figure 6). The correlation of predicted VO2max and measured VO2max
against normalised level of OHA gave R2 = 0.8589. The formula for the marker compound matched
that of 11 compounds in the Metlin database [23] although there are no MS/MS spectra for any of
these compounds in the database. Only seven of these compounds have an amine group which would
be required for the retention time to be 13.2 min on the HILIC column as observed for the current
compound. Three of the isomers occur in the lysine degradation pathway. The marker is an abundant
compound in urine and two main isomers of it occur in urine with the marker compound the later
running of the pair of isomers (extracted ion trace Figure 7).
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Figure 6. Plot of measured against predicted VO2max against normalised levels of OHA.
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Figure 7. Extracted ion trace for OHA isomers in urine comparing a pre- and post-exercise sample for
samples D2S1 and D2S3 for a subject with VO2max 53.4.
The MS2 spectrum (Figure S5) showed losses of formic acid and water, confirming the presence of
a carboxylic acid group followed by loss of a hydroxyl group but not much else. Since it seemed likely
that this marker compound was in the lysine degradation pathway, another model was constructed to
include all the metabolites present in the samples identified or putatively identified as being in the
lysine degradation pathway according to the database search. Although it was possible to fit apparently
strong models using several of these variables it was clear from the non-significant CVANOVA scores
that using several variables produced over-fitting and the majority of the predictive power belonged
to OHA. Table 2 shows all the predicted values for VO2max based on a linear plot of the normalised
levels for OHA for each individual in each sample collected on day 2. The D2S3 samples have the best
predictive power although some of the other data points are predictive and this was generally in the
case for the samples that did not have a strong spike in OHA post-exercise and hence are those with
lower VO2max values. Thus, clearly, the most important marker of VO2max is the compound putatively
identified as OHA. The candidate marker compound was also assessed by using an alternative method
of normalisation based on absolute peak areas. It was observed that the OHA isomer remained
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relatively constant between D2S1 and D2S3 in comparison to OHA. The plot shown in figure S6 plots
VO2max against the following ratio:
pareaOHAD2S3{areaOHA isomerD2S3q{pareaOHAD2S1{areaOHA isomerD2S1q
This simpler treatment produces a plot with R2 = 0.654. Although the R2 value for this plot is not as
good as the peak area normalised to individual metabolic output this gives some confidence that the
observation is not an artefact of the data pre-treatment which introduces additional smoothing into the
data. Thus, OHA shows some promise as a predictor of VO2max.
Table 2. Predicted VO2max values for all samples based on normalised response for OHA.
Primary ID Set OAHA Normalised Level VO2max Predicted VO2max
105 D2S3 0.431 40 38.5
65 D2S3 0.464 40.7 38.9
51 D2S3 0.800 38.2 42.2
24 D2S3 1.225 48.3 46.5
91 D2S3 0.917 41.7 43.4
12 D2S3 1.749 53.4 51.7
118 D2S3 0.717 40.4 41.4
78 D2S3 0.000 33.5 34.3
37 D2S3 0.633 43 40.6
128 D2S3 1.554 47.9 49.7
108 D2S1 1.000 40 44.2
68 D2S1 1.069 40.7 44.9
54 D2S1 2.544 38.2 59.6
27 D2S1 1.532 48.3 49.5
94 D2S1 2.152 41.7 55.7
15 D2S1 0.335 53.4 37.6
121 D2S1 1.994 40.4 54.1
81 D2S1 1.989 33.5 54.1
40 D2S1 2.850 43 62.6
133 D2S1 0.399 47.9 38.2
107 D2S2 0.418 40 38.4
67 D2S2 0.812 40.7 42.3
53 D2S2 0.777 38.2 42.0
26 D2S2 0.634 48.3 40.6
93 D2S2 0.318 41.7 37.4
14 D2S2 1.624 53.4 50.4
120 D2S2 1.180 40.4 46.0
80 D2S2 1.419 33.5 48.4
39 D2S2 0.948 43 43.7
132 D2S2 1.320 47.9 47.4
103 D2S4 1.705 40 51.2
63 D2S4 1.384 40.7 48.0
49 D2S4 0.398 38.2 38.2
22 D2S4 0.867 48.3 42.9
89 D2S4 1.014 41.7 44.4
10 D2S4 0.937 53.4 43.6
116 D2S4 0.706 40.4 41.3
76 D2S4 0.666 33.5 40.9
35 D2S4 0.392 43 38.2
129 D2S4 1.671 47.9 50.9
101 D2S5 1.446 40 48.7
61 D2S5 1.270 40.7 46.9
47 D2S5 0.481 38.2 39.1
20 D2S5 0.743 48.3 41.7
87 D2S5 0.599 41.7 40.2
8 D2S5 0.355 53.4 37.8
114 D2S5 0.403 40.4 38.3
74 D2S5 0.926 33.5 43.5
33 D2S5 0.177 43 36.0
127 D2S5 0.057 47.9 34.8
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4. Discussion
Comparing the compounds responsible for the separation between D2S1 and D2S3, the
post-exercise samples have higher levels of the purine metabolites hypoxanthine, guanine,
deoxyinosine, inosine, and xanthosine. Increases in purine metabolites following exercise been
observed for many years athough the focus is usually on hypoxanthine [24–29]. In our previous study
we observed the same wider effect on several purine metabolites as is observed in the current data [12].
None of the above purines are significantly changed between D1S1 and D1S3 and uric acid levels
decrease between D1S1 and D1S3. Thus the “purine response” obviously requires vigorous physical
exercise rather than normal everyday activity to manifest. Methyl adenosine, dimethyladenosine,
and dimethyl guanosine all decrease significantly between D1S1 and D1S3 but no significant changes
are observed for these metabolites between D2S1 and D2S3. There are other classes of metabolites
which typify the response to acute exercise. Nonanoyl carnitine, decanoyl carnitine, and ketodecanoyl
carnitine all increase between D2S1 and D2S3. In contrast, several acylcarnitines are significantly
decreased between D1S1 and D1S3. The increase in acyl carnitines between D2S1 and D2S3 may be
related to a decreased demand for fatty acids during a short bout of exercise where there is a switch
towards glycolysis and in order to maintain ATP levels under conditions of high oxygen demand.
Fatty acids are removed from the mitochondria as their carnitine conjugates in order to allow acetyl
CoA to enter the Krebs cycle. Panthothenic acid levels have been observed to rise following exercise
previously and this is the case in the current study where there is an increase between D2S1and D2S3
whereas there is a decrease between D1S1 and D1S3. It has been proposed that increased levels of
pantothenate in urine might indicate an increased requirement for CoA but it is more likely that
this indicates inhibition of CoA biosynthesis which is tightly regulated by pantothenate kinase (PK)
activity [30]. Acetyl CoA inhibits PK by allosteric binding and an increase in pantothenate indicates
a decrease in CoA biosynthesis. Fatty acid oxidation requires an excess of CoA and a decrease in
CoA levels would decrease fatty acid oxidation since it is energetically more favourable to rely on
oxidation of acetyl CoA generated from glycolysis in the Krebs cycle. Lactate as the end product of
glycolysis increases between D2S1 and D2S3 (Table 1) but there is no change between D1S1 and D1S3
(Table 1). Increased lactate indicates that not all the pyruvate produced by glycolysis can be used by
the Krebs cycle which mainly produces energy on the form of NADH which has to oxidised via the
terminal respiratory chain in order to yield ATP and thus requires oxygen. The adrenaline metabolite
metanephrine is elevated post-exercise as is methoxyhydroxy phenylethyleneglycol sulfate which is
also a metabolite of adrenaline. Increases in adrenaline metabolites post-exercise have been observed
previously [31]. GABA levels are lower after exercise and the GABA metabolites oxobutanoate and
hydroxy butyrate sulfate are elevated. Dihydroxyphenyl lactate, dihydroxybenzoate, and phenacetyl
glycine acid are elevated between D2S1 and D2S3 and these are generally regarded as being products
of gastrointestinal bacterial action. Elevation of microbial products has previously been reported
post-exercise [9,32]. These metabolites were not changed between D1S1 and D1S3. Testosterone
sulphate is elevated between D2S1 and D2S3 which might reflect and increase in testosterone levels
post-exercise which has been observed previously and linked to increased anabolic metabolism [33].
Similarly, the hydrocortisone metabolite tetrahydroaldosterone glucuronide is elevated post-exercise
and relects the fact the hydrocortisone is strongly involved in energy metabolism and it has been
proposed that it is directly involved in nitric oxide production [34–36]. There are three bile acids
which are important in the separation between D2S1and D2S3. Two of the bile acids are glucuronide
conjugates and such conjugates are used to remove excess bile acids from the body. In the current case
the levels of the conjugates fall thus indicating and possibly and increased demand for bile acids to
facilitate uptake of lipids from the gut since post exercise there is an increased requirement for fatty
acids. However, the same pattern is observed in the D1S1 and D1S3 comparison thus the demand for
bile acids seems to be at its lowest in the early morning since none of the other time points in table S1
differ significantly from the the S3 time points and both day 1 and day 2. Several amino acids and amino
acid derivatives are lowered between D2S1 and D2S3 but these changes are largely the same between
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D1S1 and D1S3. Exceptions include an elevation in an isomer of 5-hydroxytryptophan, possibly
3-hydroxytryptophan which was found to be elevated in our previous study [12] and carboxyethyl
arginine (CEA). CEA is an advanced glycation end product that has been observed previously to
occur in human urine and plasma [37,38]. This compound forms by reaction between arginine and
methylglyoxal which is formed as a side product of glycolysis and it has been shown that CEA is an
inhibitor of nitric oxide synthase [38] in which case its presence in the body where vassodilation is
required may not be desirable.
The observation of a single metabolic marker which is apparently correlated to VO2max is of great
interest. A previous study aimed to find markers which could predict VO2max and found that a model
based on a combination of 4-ethylphenylsulfate, tryptophan, γ-tocopherol, and α-hydroxyisovalerate
was predictive of VO2max in a cohort of 77 subjects with R
2 = 0.66 [39]. Although the current study
is small the single OHA marker in the current case gave R2 = 0.8589 and thus a greater degree of
correlation to VO2max than the previous study. The current study can only be considered to have
made a preliminary observation and a follow up trial with an independent cohort of subjects would be
require to definitely prove this association. The trial could be reduced in terms of sample collection
since it is the difference between the first void sample and the first post-exercise sample which is most
predictive of VO2max and with a high ratio of first post-exercise to first void sample indicating a high
VO2max as indicated by the plot shown in figure S6. Although the MW of the marker compound is
small, further work is required in order to make a definitive identification since several isomers of it
are known. A notable strength of the current study is that we were able to obtain valid determinations
of VO2max in all participants which is of vital importance in terms of assessing the predictive of any
metabolic markers. This is likely due to the fact that particpants had completed several previous
maximal exercise tests prior to participation in the present study. This is an important point to consider
for future larger scale research work in this area.
5. Conclusions
The current study further validates our approach of collecting every urine sample over a period
of time and then normalising each individual to their total output for each metabolite over that time.
This approach allowed separation of pre- and post-exercise samples based on PCA analysis whereas
without using this approach the separation was not possible. In our previous study we observed many
of the changes which can be seen in the current study but there were also more changes in microbial
metabolites, amino acids metabolites, acyl carnitines, and steroids [12]. The current results clearly
revealed the impact of exercise on established markers for exercise such as hypoxanthine and inosine
and, in addition, many other compounds were affected by exercise. In order to differentiate metabolites
which vary through the day and those affected by exercise the metabolites which varied during the
non-exercise day were evaluated. Some of these were the same as the metabolites changing on the
non-exercise day such as bile acid metabolites but there were many metabolites which were affected
only by exercise. A potential predictive marker for VO2max was identified but further trials will be
required to determine whether or not this is an artefact of the large number of metabolites available as
variables. The approach of collecting longitudinal urine samples is simple and non-invasive and the
observed output gives real sense of metabolism in action and could have a role in assessing overall
fitness and diagnosing underlying disease.
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